SEP 30, 2015 07:30 AM PDT
How do I choose? Androgen Biosynthesis Inhibitor, Androgen Receptor Antagonist, or both for treatment of mCRPC?
Presented at the Cancer Research and Oncology Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: CE
2 14 1006

Speakers:
  • Director of Research, CPI & Attending Urologist, The Urology Center of Colorado
    Biography
      Dr. Karsh has practiced Urology in Denver since 1984 and was board Certified in 1986, completing the most recent recertification in 2013. He graduated from the Chicago Medical School and completed his General Surgical training at The University of Colorado Health Sciences Center under Dr. Thomas Starzl. He completed his Urology residency at Brigham and Women's Hospital/Harvard Medical School under Dr. Ruben Gittes.

      Dr. Karsh is a co-founder of The Urology Center of Colorado where he serves as an attending Urologist and Director of Research. He is a principal investigator with an experience of more than 160 clinical trials. He is a Certified Principal Investigator, certified by the Association of Clinical Research Professionals (ACRP.) Dr. Karsh has authored a number of peer-reviewed publications and serves on the editorial boards for "Urologists in Cancer Care" and "Bladder Cancer." He is an active member of the AUA, ASCO, SWOG as well as the SUO. He serves on the bladder cancer subcommittee for the SUO Clinical Trials Consortium and is a member of the Denver Academy of Surgeons.

      Dr. Karsh serves as an advisor and consultant to the pharmaceutical industry, participating in drug development and research protocols. He educates physicians across the country about newly approved therapies.

      In his spare time, Dr. Karsh is an avid road bicycler and skier.

    Abstract:
    The landscape for treatment options in metastatic castration resistant prostate cancer has changed dramatically since 2010. There have been more therapies approved since 2010 than in the prior 3 decades. The purpose of this program is to outline the therapies that have been approved since 2010 and focus on the oral therapies, in particular Abiraterone and Enzalutamide. A practical discussion will include the mechanisms of action, the clinical trials resulting in approval by the FDA, the indications for their use and potential side effects. I will briefly discuss resistance mechanisms including ARV 7 splice variant and will discuss combination therapies in development. I will conclude the program with strategies for sequencing the new landscape of therapeutic options. The program will include audience questions and answers.

    Show Resources
    Loading Comments...